VIA Pharmaceuticals to Present at Seventh Annual Needham & Company Biotechnology and Medical Technology Conference

SAN FRANCISCO, June 3 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that Lawrence K. Cohen, PhD, president and chief executive officer of VIA, and James G. Stewart, senior vice president and chief financial officer, will present a company update at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference on Wednesday, June 11, 2008 at 2 p.m. ET at the New York Palace Hotel in New York City.

Interested parties may access a live audio webcast of the presentation from the investor section of the VIA website, http://www.viapharmaceuticals.com. A replay of the presentation will be archived on the VIA website for at least one week following the presentation.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple Phase 2 clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.

SOURCE VIA Pharmaceuticals, Inc.

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.